Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1445, Issue 1, 1999, Pages 86-98

  Mestre, Béatrice ^a,c   Arzumanov, Andrey ^a   Singh, Mohinder ^a   Boulmé, Florence ^b,d   Litvak, Simon ^b   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d Inst Biochem and Molec Cell Biol   (Austria)

Author keywords

HIV 1; Oligonucleotide; TAR RNA; Tat protein

Indexed keywords

2' O METHYLOLIGORIBONUCLEOTIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; FRAMYCETIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; MOLECULAR RECOGNITION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA ANALYSIS;

AMINO ACID SEQUENCE; BINDING, COMPETITIVE; GENE PRODUCTS, TAT; HIV-1; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDE FRAGMENTS; RNA, VIRAL; TRANS-ACTIVATION (GENETICS);

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033553127     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(99)00019-6     Document Type: Article

References (51)

1. J. Karn, M.J. Churcher, K. Rittner, N. Keen, M.J. Gait, Control of transcriptional elongation by the human immunodeficiency virus tat protein, in: S. Goodbourn (Ed.), Eukaryotic Gene Transcription, Oxford University Press, Oxford, 1996, pp. 254-286.
2. P. Wei, M.E. Garber, S.-M. Fang, W.H. Fischer, K.A. Jones, A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA, Cell 92 (1998) 451-462.
3. K. Fujinaga, T.P. Cujec, J. Peng, J. Garriga, D.H. Price, X. Grana, M. Peterlin, The ability of positive transcription elongation factor b to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat, J. Virol. 72 (1998) 7154-7159.
4. N.J. Keen, M.J. Churcher, J. Karn, Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex, EMBO J. 16 (1997) 5260-5272.
5. H. Mancebo, G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, C. Blau, D. Hazuda, D. Price, O. Flores, P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro, Genes Dev. 11 (1997) 2633-2644.
6. S. Nekhai, R.R. Shukla, A. Kumar, A human primary T-lymphocyte-derived human Immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity, J. Virol. 71 (1997) 7436-7441.
7. J. Kamine, P. Loewenstein, M. Green, Mapping of HIV-1 tat protein sequences required for binding to TAR RNA, Virology 182 (1991) 570-577.
8. M.J. Churcher, C. Lamont, F. Hamy, C. Dingwall, S.M. Green, A.D. Lowe, P.J.G. Butler, M.J. Gait, J. Karn, High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region, J. Mol. Biol. 230 (1993) 90-110.
9. C. Dingwall, I. Ernberg, M.J. Gait, S.M. Green, S. Heaphy, J. Karn, A.D. Lowe, M. Singh, M.A. Skinner, R. Valerio, Human immunodeficiency virus 1 tat protein binds transactivation-responsive region (TAR) RNA in vitro, Proc. Natl. Acad. Sci. USA 86 (1989) 6925-6929.
10. C. Dingwall, I. Ernberg, M.J. Gait, S.M. Green, S. Heaphy, J. Karn, A.D. Lowe, M. Singh, M.A. Skinner, HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure, EMBO J. 9 (1990) 4145-4153.
11. S. Roy, U. Delling, C.-H. Chen, C.A. Rosen, N. Sonenberg, A bulge structure in HIV-1 TAR RNA is required for tat binding and tat-mediated trans-activation, Genes Dev. 4 (1990) 1365-1373.
12. W.E.G. Müller, T. Okamoto, P. Reuter, D. Ugarkovic, H.C. Schröder, Functional characterization of tat protein from human immunodeficiency virus: evidence that tat links viral RNAs to nuclear matrix, J. Biol. Chem. 265 (1990) 3803-3808.
13. U. Delling, L.S. Reid, R.W. Barnett, M.X.Y. Ma, S. Climie, M. Sumner-Smith, N. Sonenberg, Conserved nucleotides in the TAR RNA stem of human immunodeficiency virus type 1 are critical for tat binding and trans activation: model for TAR RNA tertiary structure, J. Virol. 66 (1992) 3018-3025.
14. M.-C. Hsu, A.D. Schutt, M. Holly, L.W. Slice, M.I. Sherman, D.D. Richman, M.J. Potash, D.J. Volsky, Inhibition of HIV replication in acute and chronic infections in vitro by a tat antagonist, Science 254 (1991) 1799-1802.
15. W.F. Michne, J.D. Schroeder, T.R. Bailey, H.C. Neumann, D. Cooke, D.C. Young, J.V. Hughes, S.D. Kingsley, K.A. Ryan, H.S. Putz, L.J. Shaw, F.J. Dutko, Keto/enol epoxy steroids as HIV-1 Tat inhibitors: structure-activity relationships and pharmacophore localization, J. Med. Chem. 38 (1995) 3197-3206.
16. D.L. Coffen, T.-N. Huang, S.E. Ramer, R.C. West, E.V. Connell, A.D. Schutt, M.-C. Hsu, Discovery of a drug lead employing a peptide library: inhibition of HIV-1 tat and viral replication by the tripeptide YPG-NH2, Antiviral Chem. Chemother. 5 (1994) 128-129.
17. I. Huq, X. Wang, T.M. Rana, Specific recognition of HIV-1 TAR RNA by a D-Tat peptide, Nat. Struct. Biol. 4 (1997) 881-882.
18. X. Wang, I. Huq, T.M. Rana, HIV-1 TAR recognition by an unusual bipolymer, J. Am. Chem. Soc. 119 (1997) 6444-6445.
19. F. Hamy, E.R. Felder, G. Heizmann, J. Lazdins, F. Aboulela, G. Varani, J. Karn, T. Klimkait, An inhibitor of the Tat/ TAR interaction that effectively suppresses HIV-1 replication, Proc. Natl. Acad. Sci. USA 94 (1997) 3548-3553.
20. H.-Y. Mei, D.P. Mack, A.A. Galan, N.S. Halim, A. Heldsinger, J.A. Loo, D.W. Moreland, K.A. Sannes-Lowery, L. Sharmeen, H.N. Truong, A.W. Czarnik, Discovery of selective, small-molecule inhibitors of RNA complexes. I. The Tat protein/TAR RNA complexes required for HIV-1 transcription, Bioorg. Med. Chem. 5 (1997) 1173-1184.
21. L. Dassonneville, F. Hamy, P. Colson, C. Houssier, C. Bailly, Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure, Nucleic Acids Res. 25 (1997) 4487-4492.
22. F. Hamy, V. Brondani, A. Flörsheimer, W. Stark, M.J.J. Blommers, T. Klimkait, A new class of HIV-1 antagonists acting through Tat-TAR inhibition, Biochemistry 37 (1998) 5086-5095.
23. G. Degols, J.-P. Leonetti, P. Milhaud, N. Mechti, B. Lebleu, Antisense inhibitors of HIV: problems and perspectives, Antiviral Res. 17 (1992) 279-287.
24. S. Akhtar, J.J. Rossi, Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?, J. Antimicrob. Chemother. 38 (1996) 159-165.
25. T. Vickers, B.F. Baker, P.D. Cook, M. Zounes, R.W.J. Buckheit, J. Germany, D.J. Ecker, Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element, Nucleic Acids Res. 19 (1991) 3359-3368.
26. B. Bordier, M. Perala-Heape, G. Degols, B. Lebleu, S. Litvak, L. Sarih-Cottin, C. Hélène, Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells, Proc. Natl. Acad. Sci. USA 92 (1995) 9383-9387.
27. F. Boulmé, M. Perälä-Heape, L. Sarih-Cottin, S. Litvak, Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2, Biochim. Biophys. Acta 1351 (1997) 249-255.
28. F. Boulmé, F. Freund, S. Moreau, P. Nielsen, S. Gryaznov, J.-J. Toulmé, S. Litvak, Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcriptase, Nucleic Acids Res. 26 (1998) 5492-5500.
29. T. Johnson, M. Quibell, D. Owen, R.C. Sheppard, A reversible protecting group for the amide bond in peptides. Use in the synthesis of 'difficult sequences', J. Chem. Soc. Chem. Commun. (1993) 369-372.
30. M. Quibell, W.G. Turnell, T. Johnson, Preparation of β-amyloid (1-43) via soluble, amide protected intermediates, J. Org. Chem. 59 (1994) 1745-1750.
31. M. Quibell, L.C. Packman, T. Johnson, Solid phase assembly of backbone amide-protected peptide segments: an efficient and reliable strategy for the synthesis of small proteins, J. Chem. Soc. Perkin I (1996) 1227-1234.
32. M.J. Gait, C.E. Pritchard, G. Slim, Oligoribonucleotide synthesis, in: F. Eckstein (Ed.), Oligonucleotides and Analogues: a Practical Approach, Oxford University Press, Oxford, 1991, pp. 25-48.
33. S. Schmidt, R.L. Grenfell, J. Fogg, T.V. Smith, J.A. Grasby, K. Mersmann, M.J. Gait, Solid phase synthesis of oligoribonucleotides containing site-specific modifications, in: R. Epton (Ed.), Innovation and Perspectives in Solid Phase Synthesis and Combinatorial Libraries, 4th Int. Symp. Proc. 1996, Mayflower, Birmingham, 1996, pp. 11-18.
34. N.A. Naryshkin, M.A. Farrow, M.G. Ivanovskaya, T.S. Orestkaya, Z.A. Shabarova, M.J. Gait, Chemical cross-linking of the HIV type-1 Tat protein to synthetic models of the RNA recognition sequence TAR containing site-specific tri-substituted pyrophosphate analogues, Biochemistry 36 (1997) 3496-3505.
35. M.A. Farrow, F. Aboul-ela, D. Owen, A. Karpeisky, L. Beigelman, M.J. Gait, Site-specific cross-linking of amino acids in the basic region of human immunodeficiency virus type 1 Tat peptide to chemically modified TAR RNA duplexes, Biochemistry 37 (1998) 3096-3108.
36. M.J. Gait, D.J. Earnshaw, M.A. Farrow, J.H. Fogg, R.L. Grenfell, N.A. Naryshkin, T.V. Smith, Applications of chemically synthesized RNA, in: C. Smith (Ed.), RNA-Protein Interactions: a Practical Approach, Oxford University Press, Oxford, 1998, pp. 1-36.
37. J. Karn, M.J. Churcher, K. Rittner, A. Kelley, P.J.G. Butler, D.A. Mann, M.J. Gait, RNA binding assays for the regulatory proteins Tat and Rev, in: J. Karn (Ed.), HIV. A Practical Approach, Oxford University Press, Oxford, 1995, pp. 147-165.
38. F. Hamy, U. Asseline, J.A. Grasby, S. Iwai, C.E. Pritchard, G. Slim, P.J.G. Butler, J. Karn, M.J. Gait, Hydrogen-bonding contacts in the major groove are required for human immunodeficiency virus type-1 tat protein recognition of TAR RNA, J. Mol. Biol. 230 (1993) 111-123.
39. R.W. Wagner, M.D. Matteucci, J.G. Lewis, G.A.J., C. Moulds, B.C. Froehler, Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines, Science 260 (1993) 1510-1513.
40. W.M. Flanagan, A. Kothavale, R.W. Wagner, Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency, Nucleic Acids Res. 24 (1996) 2936-2941.
41. H. Inoue, Y. Hayase, A. Imura, S. Iwai, K. Miura, E. Ohtsuka, Synthesis and hybridization studies on two complementary nona-2′-O-methylribooligonucleotides, Nucleic Acids Res. 15 (1987) 6131-6148.
42. A.I. Lamond, B.S. Sproat, Antisense oligonucleotides made of 2′-O-alkyl RNA: their properties and application in RNA biochemistry, FEBS Lett. 325 (1993) 123-127.
43. M. Majlessi, N.C. Nelson, M.M. Becker, Advantages of 2′-O-methyl oligoribonucleotide probes for detecting RNA targets, Nucleic Acids Res. 26 (1998) 2224-2229.
44. C. Dingwall, I. Ernberg, M.J. Gait, S. Heaphy, M.A. Skinner, J. Karn, HIV-1 tat binds TAR RNA in vitro, Georg-Speyer Haus J. 1 (1990) 30-33.
45. S. Agrawal, J. Tang, GEM 91: an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS, Antisense Res. Dev. 2 (1992) 261-266.
46. C. Stein, Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides, Chem. Biol. 3 (1996) 319-323.
47. B. Larrouy, C. Boiziau, B. Sproat, J.-J. Toulmé, RNase H is responsible for the non-specific inhibition of in vitro translation by 2′-O-alkyl chimeric oligonucleotides: high affinity or selectivity, a dilemma to design antisense oligomers, Nucleic Acids Res. 23 (1995) 3434-3440.
48. S.T. Crooke, Delivery of oligonucleotides and polynucleotides, J. Drug Targeting 3 (1995) 185-190.
49. E. Vivès, B. Lebleu, Selective coupling of a highly basic peptide to an oligonucleotide, Tetrahedron Lett. 38 (1997) 1183-1186.
50. E. Vivès, P. Brodin, B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J. Biol. Chem. 272 (1997) 16010-16017.
51. C.-H. Tung, J. Wang, M.J. Leibowitz, S. Stein, Dual-specificity interaction of HIV-1 TAR RNA with Tat peptide-oligonucleotide conjugates, Bioconjugate Chem. 6 (1995) 292-295.